Pretreatment clinical characteristics (N = 635 patients)
Data | |
| Age, median (range), y | 68 (60-86) |
| Age distribution, no. (%) | |
| 60-69 y | 373 (58.7) |
| 70-79 y | 233 (36.7) |
| 80 y or older | 29 (4.6) |
| Sex, male, no. (%) | 346 (54.5) |
| Race, no. (%) | |
| White | 568 (89.5) |
| Black | 49 (7.7) |
| Hispanic | 11 (1.7) |
| Other | 7 (1.1) |
| FAB classification, no. (%) | |
| M0 | 14 (2.2) |
| M1 | 134 (21.1) |
| M2 | 234 (36.9) |
| M4 | 126 (19.8) |
| M5 | 70 (11.0) |
| M6 | 18 (2.8) |
| M7 | 4 (0.6) |
| Unclassified | 35 (5.5) |
| De novo AML, no. (%) | 619 (97.5) |
| WBC, median (range), × 109/L | 13.8 (0.5-450.0) |
| Hemoglobin level, median (range), g/dL | 9.4 (3.0-15.4) |
| Platelet count, median (range), × 109/L | 64 (2-1200) |
| Percentage myeloblasts in marrow, median (range) | 65 (20-98) |
| Percentage myeloblasts in blood, median (range) | 48 (0-99) |
| CNS involvement, % | 1 |
| Splenomegaly, % | 7 |
| Hepatomegaly, % | 9 |
| Gum hypertrophy, % | 7 |
| Lymphadenopathy, % | 7 |
| Skin infiltration, % | 7 |
| Mediastinal mass, % | 1 |
Data | |
| Age, median (range), y | 68 (60-86) |
| Age distribution, no. (%) | |
| 60-69 y | 373 (58.7) |
| 70-79 y | 233 (36.7) |
| 80 y or older | 29 (4.6) |
| Sex, male, no. (%) | 346 (54.5) |
| Race, no. (%) | |
| White | 568 (89.5) |
| Black | 49 (7.7) |
| Hispanic | 11 (1.7) |
| Other | 7 (1.1) |
| FAB classification, no. (%) | |
| M0 | 14 (2.2) |
| M1 | 134 (21.1) |
| M2 | 234 (36.9) |
| M4 | 126 (19.8) |
| M5 | 70 (11.0) |
| M6 | 18 (2.8) |
| M7 | 4 (0.6) |
| Unclassified | 35 (5.5) |
| De novo AML, no. (%) | 619 (97.5) |
| WBC, median (range), × 109/L | 13.8 (0.5-450.0) |
| Hemoglobin level, median (range), g/dL | 9.4 (3.0-15.4) |
| Platelet count, median (range), × 109/L | 64 (2-1200) |
| Percentage myeloblasts in marrow, median (range) | 65 (20-98) |
| Percentage myeloblasts in blood, median (range) | 48 (0-99) |
| CNS involvement, % | 1 |
| Splenomegaly, % | 7 |
| Hepatomegaly, % | 9 |
| Gum hypertrophy, % | 7 |
| Lymphadenopathy, % | 7 |
| Skin infiltration, % | 7 |
| Mediastinal mass, % | 1 |
FAB indicates French-American-British; WBC, white blood cell count; and CNS, central nervous system.
*Percentage of myeloblasts may be less than 30% in cases of AML-M6.